Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Completed 2

Sponsor Class

NIH 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

CNS 2Sarcoma 1

Conditions

Brain Neoplasms 2Oligodendroglioma 1Gliosarcoma 1Glioblastoma 1Central Nervous System Neoplasms 1Astrocytoma 1

Interventions

Temozolomide 163Radiosurgery 129Radiotherapy 107Bevacizumab 98Magnetic Resonance Spectroscopy 75Carboplatin 48Surgical Procedures, Operative 35pembrolizumab 34Radiation 34Etoposide 34Nivolumab 33Irinotecan 33Cyclophosphamide 33Erlotinib Hydrochloride 31Carmustine 28Trastuzumab 25Lomustine 25Cisplatin 25Ipilimumab 24Filgrastim 23Mental Status and Dementia Tests 21Magnetic Resonance Imaging 21Aminolevulinic Acid 21Vincristine 20Surveys and Questionnaires 19Capecitabine 19Topotecan 18Specimen Handling 18Pemetrexed 18Radiotherapy, Intensity-Modulated 16

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Brain Neoplasms × cositecan × CNS × Clear all
NCT00062478 2020-03-12

Study of Karenitecin (BNP1350) in Patients With Brain Tumors

BioNumerik Pharmaceuticals, Inc.

Phase 2 Completed
40 enrolled
CNS

Brain Neoplasms

NCT00014521 2008-07-24

Karenitecin in Treating Patients With Recurrent Malignant Glioma

National Cancer Institute (NCI)

Phase 1 Completed
CNSSarcoma

Astrocytoma, Brain Neoplasms, Glioblastoma, Oligodendroglioma, Central Nervous System Neoplasms, Gliosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡